Abstract:Background and purpose:Tumor vasculature is increasingly recognized as a target for cancer therapy.In recent years,a fusion protein consisting of the extra cellular domain of tissue factor(truncated tissue factor,tTF)was fused to the antibody selectively binding to tumor vasculature.Antibody-truncated tissue factor(Ab-tTF)fusion protein specifi cally induced thrombotic occlusion of tumor vessels resulting in tumor growth retardation or regression in some types of solid tumors.However,there were still some disadvantages in the above approach.We constructed and expressed that the(RGD)3-tTF fusion protein with peptides arginine-glycine-aspartic acid(GRGDSP,abbr.RGD)as the carrier of tTF to explore whether it had the capability of targeting to tumor vasculature in the colonic carcinoma model.Methods:The(RGD)3-tTF fusion gene consisting of the tTF was fused to three series-wound peptides RGD.The(RGD)3-tTF construct was expressed in Escherichia coli BL21(DE3).The fusion protein was purifi ed through Nickel affi nity chromatography column.The activity of inducing blood coagulation was detected by clotting assay and coagulation factor Ⅹ(FⅩ)activation assay.The specific binding to integrins αvβ3 was analyzed by indirect enzyme linked immunosorbent assay(ELISA).All these were compared with the fusion protein RGD-tTF.Colonic nude mice models were randomly divided into 3 groups(1 nude mice per group).Tumors were stained by the(RGD)3-tTF,RGD-tTF fusion protein and tTF which were labeled with Fluorescein Isothiocyanate(FITC).The location of the(RGD)3-tTF fusion protein in the colonic carcinoma bearing nude mice tissue was analyzed by immuno? uorescence assay.Results:The(RGD)3-tTF fusion protein retained tissue factor thrombogenic activities.With increasing concentration,the clotting time was shortened correspondingly.Under the conditions of Ca2+,the clotting time was 9.96 ± 0.56 min when the concentration was 6 μmol/L(P0.01).The(RGD)3-tTF fusion protein could activise FⅩ above 6 μmol/L concentration,which was similar to RGD-tTF fusion(F=0.147,P0.05).The ability of the(RGD)3-tTF fusion protein binding specifi cally to integrins αvβ3 was stronger than that of the RGD-tTF fusion protein in the same concentration(F=164.81,P0.01),which was apparently indicated by the A405nm 1.25 and 0.95 when the concentration was 0.24 μmol/L.Immuno? uorescence assay showed that the(RGD)3-tTF fusion protein was assembling in the tumor vasculature of the colonic carcinoma bearing nude mice.Conclusion:The(RGD)3-tTF fusion protein which retained tissue factor thrombogenic activities could bind specifi cally and effi ciently to tumor vasculature in the colonic carcinoma bearing mice through binding to the tumor marker integrins αvβ3.It might be a promising foundation for further studies on the colon cancer molecular targeted therapy with tTF as an effective factor.

Experimental Study Of(rgd)_3-Ttf Fusion Proteins Binding Specifi Cally to Tumor Vasculature in the Colonic Carcinoma Nude Mice Model

Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)3 -tTF

Capacity of Thrombosis Targeting Protein (Rgd)_3-Ttf Specific Binding to Tumor Vasculature Markers Integrin Α_vβ_3

[Arginine-Glycine-aspartic Polypeptide Mediated Truncated Tissue Factor Therapy for Colorectal Carcinoma].

Comparison of Three Different Targeted Tissue Factor Fusion Proteins for Inducing Tumor Vessel Thrombosis.

Gene Expression and Activity Analysis of a Novel Fusion Protein (Rgd)3/ttf

Enhancement of Anti-Tumor Properties of Trail by Targeted Delivery to the Tumor Neovasculature

Humanized Monoclonal Antibody TNT-3-mediated Truncated Tissue Factor for the Treatment of H22hepatoma-bearing Mice

A Recombined Fusion Protein SP5.2/tTF Induce Thrombosis in Tumor Blood Vessel.

Application of RGD Ligands Targeting Integrin α_vβ_3 in Anti-tumor Angiogenesis

Antitumor Effect of FP3 on a Patient-Derived Tumor Tissue Xenograft Model of Rectal Carcinoma.

Tumor uptake of the RGD dimeric probe99mTc-G3-2P 4-RGD2 is correlated with integrin αv/β 3 expressed on both tumor cells and neovasculature

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

Purification and Characterization of Rgd Tumor-Homing Peptide Conjugated Human Tumor Necrosis Factor Alpha Over-Expressed in Escherichia Coli

Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo

Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels.

In Vivo and in Vitro Studies of 99Tcm-3P-rgd2 Targeting Integrin Αvβ3 in Lung Cancer

Molecular Basis For The Targeted Binding Of Rgd-Containing Peptide To Integrin Alpha(V)Beta(3)

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Molecular basis for the targeted binding of RGD-containing peptide to integrin αVβ3.

Expression Levels of Integrin Αvβ3 Versus Tumor Uptake of 99Mtc-Labeled RGD Peptide